SELLAS Life Sciences Group, Inc.
SLSNext catalyst
SLS009
Hematologic Malignancies
Get an email about SLS's next catalysts
Track SELLAS Life Sciences Group (SLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
SLS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
SLS009 Phase 2 Est. Readout
Primary completion for SLS009 trial (NCT04588922) in Hematologic Malignancies
SourceMarket Overview
Stock performance and key metrics
Galinpepimut-S
Acute Myeloid Leukemia
Galinpepimut-S + Montanide + GM-CSF
Malignant Pleural Mesothelioma
SLS009
Hematologic Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia | - | - |
Galinpepimut-S + Montanide + GM-CSF | Phase 2 | Malignant Pleural Mesothelioma | - | - |
SLS009 | Phase 2 | Hematologic Malignancies | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in SELLAS Life Sciences Group, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in SELLAS Life Sciences Group, Inc.'s (SLS) pipeline across Phase 3, Phase 2. Its lead program is Galinpepimut-S (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SELLAS Life Sciences Group, Inc.'s next FDA catalyst?→
SELLAS Life Sciences Group, Inc.'s (SLS) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SLS biotech catalysts?→
Add SLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SELLAS Life Sciences Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.